RxDoctor Payments Data

Angela Lowenstern, MD

Interventional Cardiology · Nashville, TNNPI 1235405796

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (48.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 82.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $21,000 and has fallen 54.6% since, to $9,531 in 2025.

$43,047in general payments, 2019–2025

Across 81 payments — averaging $531.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$36K
  • Edwards Lifesciences$5K
  • Boston Scientific$981
  • Abbott$590
  • Teleflex LLC$274
  • Opsens Inc.$181
  • plus $287 from 4 others

What the payments were for

  • Consulting fees$3,5008%
  • Speaking & faculty fees$7,07616%
  • Grants$21,00049%
  • Travel & lodging$7,03916%
  • Food & beverage$4,43210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,047 in reported general payments places this provider in the 80th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$154,957
Medicare patients
323
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan25$49,963
JardianceEmpagliflozin46$49,194
Repatha SureclickEvolocumab44$43,355
EliquisApixaban18$25,581
XareltoRivaroxaban16$13,896
FarxigaDapagliflozin Propanediol13$10,865
Metoprolol Succinate52$1,043
Atorvastatin Calcium87$1,026
ClopidogrelClopidogrel Bisulfate44$648
Ezetimibe21$562
Isosorbide Mononitrate ErIsosorbide Mononitrate19$503
Losartan Potassium27$444
Rosuvastatin Calcium25$352
Metoprolol Tartrate42$315
Amlodipine Besylate45$307

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →